PL2325648T3 - Sposób wykrywania nowotworów - Google Patents

Sposób wykrywania nowotworów

Info

Publication number
PL2325648T3
PL2325648T3 PL09805010T PL09805010T PL2325648T3 PL 2325648 T3 PL2325648 T3 PL 2325648T3 PL 09805010 T PL09805010 T PL 09805010T PL 09805010 T PL09805010 T PL 09805010T PL 2325648 T3 PL2325648 T3 PL 2325648T3
Authority
PL
Poland
Prior art keywords
detecting cancer
cancer
detecting
Prior art date
Application number
PL09805010T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Kana Suzuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2325648T3 publication Critical patent/PL2325648T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL09805010T 2008-08-05 2009-08-05 Sposób wykrywania nowotworów PL2325648T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008202320 2008-08-05
PCT/JP2009/063883 WO2010016527A1 (ja) 2008-08-05 2009-08-05 癌の検出方法
EP09805010.7A EP2325648B1 (en) 2008-08-05 2009-08-05 Method for detecting cancer

Publications (1)

Publication Number Publication Date
PL2325648T3 true PL2325648T3 (pl) 2014-09-30

Family

ID=41663744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09805010T PL2325648T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów
PL14153299T PL2733492T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14153299T PL2733492T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów

Country Status (16)

Country Link
US (1) US11137401B2 (pl)
EP (2) EP2733492B1 (pl)
JP (2) JP5644110B2 (pl)
KR (2) KR20160039295A (pl)
CN (1) CN102171570B (pl)
AU (2) AU2009278387B2 (pl)
BR (1) BRPI0911925B8 (pl)
CA (1) CA2732980C (pl)
DK (2) DK2733492T3 (pl)
ES (2) ES2570731T3 (pl)
HU (1) HUE027332T2 (pl)
MX (2) MX337991B (pl)
PL (2) PL2325648T3 (pl)
PT (1) PT2325648E (pl)
RU (2) RU2519089C2 (pl)
WO (1) WO2010016527A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
KR101871704B1 (ko) * 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
HUE040012T2 (hu) * 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
AU2011211699B2 (en) * 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101842893B1 (ko) * 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2629061T3 (es) * 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
ES2672695T3 (es) * 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
CN103764825B (zh) * 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101968499B1 (ko) * 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112014002619A2 (pt) * 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
PT2740796T (pt) * 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (pl) * 2012-02-21 2015-10-23 Toray Industries
AU2013223143B2 (en) * 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX357505B (es) * 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2739380T3 (es) * 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2832365T (pt) * 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP3225630B1 (en) * 2014-11-27 2021-05-12 Public University Corporation Yokohama City University Method and reagent for detecting ovarian clear cell adenocarcinoma
RU2611896C1 (ru) * 2016-03-10 2017-03-01 Федеральное государственное бюджетное учреждение здравоохранения Клиническая больница N 122 имени Л.Г. Соколова Федерального медико-биологического агентства (ФГБУЗ КБ N 122 им. Л.Г. Соколова ФМБА России) Способ диагностики лейомиомы мочевого пузыря
TWI782000B (zh) * 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗gpr20抗體、其製造方法及其應用
WO2018187512A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
RU2677064C1 (ru) * 2017-10-13 2019-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения границ резекции при лечении остеосаркомы
JP6875451B2 (ja) * 2018-09-26 2021-05-26 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム
WO2020067261A1 (ja) * 2018-09-26 2020-04-02 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム
WO2024204325A1 (ja) 2023-03-28 2024-10-03 東レ株式会社 細胞膜タンパク質を検出する方法
EP4691490A1 (en) 2023-03-31 2026-02-11 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
KR970706498A (ko) 1994-09-19 1997-11-03 리카르도 제이. 모로 암의 검사 및 치료방법(detection and treatment of cancer)
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) * 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TR200100916T2 (pl) 1998-07-14 2002-06-21 Corixa@@Corporation
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003528587A (ja) 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 27個のヒト分泌タンパク質
AU2001261007A1 (en) * 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002311909A1 (en) * 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
CA2454048C (en) 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
JP3869352B2 (ja) 2002-11-12 2007-01-17 日鉱金属株式会社 金属箔の熱量測定方法、表面特性の調整方法、レーザー穴開け方法又は熱量測定装置
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2005116076A2 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
ES2387809T3 (es) 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) * 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
PL1839662T3 (pl) 2005-01-19 2010-08-31 Zeria Pharm Co Ltd Środek przeciwnowotworowy
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006214105A1 (en) * 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
EP1869462B1 (en) 2005-03-11 2013-05-08 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) * 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP4958580B2 (ja) 2007-02-21 2012-06-20 鹿島建設株式会社 シールド機、シールド機とセグメントの間のクリアランス測定方法
PT3106873T (pt) 2007-10-25 2019-10-18 Toray Industries Método para a deteção de cancro
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
PL2324842T3 (pl) 2008-08-05 2015-08-31 Toray Industries Środek indukujący odporność
BR112012003686B1 (pt) 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
IN2014KN01714A (pl) 2012-02-21 2015-10-23 Toray Industries
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Also Published As

Publication number Publication date
US20110136121A1 (en) 2011-06-09
JP2014134550A (ja) 2014-07-24
RU2671497C2 (ru) 2018-11-01
RU2011108258A (ru) 2012-09-10
JPWO2010016527A1 (ja) 2012-01-26
HUE027332T2 (en) 2016-09-28
BRPI0911925B1 (pt) 2024-01-30
MX2011001445A (es) 2011-04-05
AU2009278387A1 (en) 2010-02-11
ES2471379T3 (es) 2014-06-26
KR20160039295A (ko) 2016-04-08
CA2732980A1 (en) 2010-02-11
AU2009278387B2 (en) 2015-07-09
AU2015238877A1 (en) 2015-10-29
DK2733492T3 (en) 2016-04-25
RU2014111182A (ru) 2015-09-27
PT2325648E (pt) 2014-06-24
EP2733492A1 (en) 2014-05-21
CN102171570B (zh) 2014-10-15
DK2325648T3 (da) 2014-07-28
RU2519089C2 (ru) 2014-06-10
US11137401B2 (en) 2021-10-05
CA2732980C (en) 2017-08-15
EP2733492B1 (en) 2016-02-24
EP2325648A4 (en) 2011-09-28
JP5644110B2 (ja) 2014-12-24
WO2010016527A1 (ja) 2010-02-11
KR20110052665A (ko) 2011-05-18
KR101606779B1 (ko) 2016-03-28
EP2325648B1 (en) 2014-04-23
ES2570731T3 (es) 2016-05-20
JP5825386B2 (ja) 2015-12-02
PL2733492T3 (pl) 2016-08-31
BRPI0911925A2 (pt) 2016-09-20
AU2015238877B2 (en) 2017-02-16
BRPI0911925B8 (pt) 2024-02-06
EP2325648A1 (en) 2011-05-25
CN102171570A (zh) 2011-08-31
MX337991B (es) 2016-03-30

Similar Documents

Publication Publication Date Title
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
PT2313364T (pt) Métodos para detectar dimetilarginina simétrica
EP2380111A4 (en) FACE DETECTION ACCELERATION METHOD
PT3106875T (pt) Método para a deteção de cancro
GB0803107D0 (en) Method
GB0818093D0 (en) Method
GB2462829B (en) Measurement method
GB0810418D0 (en) Method
GB0813599D0 (en) Method
GB0804981D0 (en) Method
GB0807409D0 (en) Method
GB0804690D0 (en) Method
GB0815428D0 (en) Method
GB0814960D0 (en) Method for detecting dysplasia
EP2321794A4 (en) RED DETECTION METHOD
GB0809404D0 (en) Method
GB0805862D0 (en) Method
GB0813494D0 (en) Method
GB0812559D0 (en) Method
EP2283148A4 (en) CYTOLOGICAL METHODS FOR CANCER SCREENING
GB0722734D0 (en) Detection method
GB0812102D0 (en) Method
EP2273283A4 (en) OBJECT DETECTOR
EP2251436A4 (en) SIRNA DETECTION METHOD
GB0813922D0 (en) Detection apparatus